Kidney Cancer Survival Rates Rose With Combo Therapies
Patients with advanced renal cell carcinoma who received combination therapies saw improved survival times in a recent study.
Updated on Oct. 13, 2026 in Cancer
Live Poll
Does medical research into new drug combinations successfully lead to better long-term survival for cancer patients?
A retrospective study of 2,123 patients in the United States found that immuno-oncology and tyrosine kinase inhibitor (IO-TKI) combination regimens were linked to longer overall survival compared to other treatments. The findings, which analyzed data from 2017 to 2024, were presented at the Kidney Cancer Research Summit on July 23-24, 2026.
Why it matters
As combination therapies have become the standard of care for advanced renal cell carcinoma, this study quantifies the survival benefits associated with these regimens. These insights help patients and clinicians weigh the improved outcomes against the higher monthly costs associated with these therapies.
A retrospective analysis of 2,123 patients tracked via the Optum Clinformatics Data Mart Database compared outcomes for various treatment regimens. The study observed a median overall survival of 44.1 months for the IO-TKI group, surpassing both IO-IO and TKI monotherapy outcomes.
The players
Kidney Cancer Research Summit
An annual medical gathering where researchers and oncologists share clinical updates and trial results for renal cell carcinoma treatments.
Optum Clinformatics Data Mart Database
A large-scale administrative claims repository used by researchers to evaluate healthcare utilization and patient survival trends.
The details
The analysis compared three primary treatment paths: IO-TKI combinations, IO-IO combinations, and TKI monotherapy. These treatments work by either stimulating the immune system to recognize and attack cancer cells or by blocking proteins called tyrosine kinases that tumors require to grow and divide. Usage of IO-TKI combinations increased from 33.8% to 48.6% between 2019 and 2024, while TKI monotherapy decreased, reflecting a shift in oncology prescribing patterns.
Timeline
2017-2024: Study period for data collection from the Optum Clinformatics Data Mart Database.
2019-2024: Period tracking shifts in first-line treatment regimen usage.
July 23-24, 2026: The study results were presented at the Kidney Cancer Research Summit.
Health Landscape
The transition toward IO-TKI combinations marks a shift in the oncology standard of care for advanced renal cell carcinoma. This trend aligns with evidence typically highlighted at the Kidney Cancer Research Summit regarding the adoption of systemic therapies.
Patients with advanced renal cell carcinoma may find it useful to discuss the survival data and cost implications of various combination therapies with their oncologist. Understanding these regimen options is an important part of the conversation when evaluating treatment plans.
The takeaway
Combination therapies for kidney cancer are increasingly common and are linked to significant survival improvements in clinical data. Ask your physician how different treatment regimens align with your specific diagnosis and long-term care goals.
Further reading
For more on treatment trends and evidence-based care, visit our Cancer section.
Source note: This article includes information reported by OncLive.
Live Poll
Does medical research into new drug combinations successfully lead to better long-term survival for cancer patients?
